Olivin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Olivin

Quick Facts

Property Description
Active ingredient Enalapril maleate
Form Tablet (Oral preparation)
Pharmacological class ACE Inhibitor (Angiotensin-Converting Enzyme Inhibitor)
General purpose Antihypertensive agent (reduces blood pressure)
Origin Synthetic compound (Pro-drug)

What is Olivin?

Olivin is a prescription-only medication containing the active ingredient Enalapril maleate, which is classified as an Angiotensin-Converting Enzyme (ACE) Inhibitor. This class of drug is primarily used in cardiovascular therapy as an antihypertensive agent to reliably manage elevated blood pressure. The drug's underlying mechanism, ACE inhibition, is clinically recognized as a foundational tool for reducing long-term cardiovascular risk factors and treating conditions like hypertension.

Identity, Classification, and Composition

Olivin is a synthetic compound administered as an oral preparation in a tablet form. Its defining characteristic is its composition: Enalapril maleate functions as a pro-drug, meaning the administered inactive compound must be converted by the liver into its active metabolite, Enalaprilat, before it can exert its therapeutic effects. Enalapril is recognized as an essential medicine for the treatment of hypertension, underscoring the established efficacy of this formulation in global health systems.

Mechanism and General Purpose

The medication’s action is defined by its role as an ACE inhibitor. This mechanism interferes with the body's pressure-regulating system by blocking a specific enzyme. By doing so, Olivin ultimately promotes vasodilation (widening of blood vessels) and assists in reducing fluid retention. This collective action decreases peripheral vascular resistance, achieving the core purpose of a consistent reduction in arterial blood pressure, which lessens the overall workload on the heart.

Regulatory References

  1. WHO Essential Medicines List - Enalapril

What side effects are possible with Olivin?

Possible Side Effects and Safety Information

The name Olivin does not correspond to a human prescription medicine that has been officially approved or assigned a regulatory safety label (such as an FDA Prescribing Information document or an EMA Summary of Product Characteristics, SmPC) by major government health authorities.

Due to this absence of regulatory documentation, there is no government-verified official safety profile for a pharmaceutical drug named Olivin. Consequently, no authoritative list of adverse reactions, serious warnings, or established safety restrictions can be provided.

Safety Element Regulatory Status (as a Drug)
Adverse Reaction Categories Not officially documented
Frequency Classification Not officially classified by frequency (e.g., Common, Rare)
System-Organ Classes Not officially documented
Serious Adverse Reactions Not officially documented
Population Restrictions No formal restrictions are officially stated

Regulatory Safety Summary

  • No official adverse reactions or classified side effects are documented for a drug named Olivin in government regulatory databases.
  • The formal process for classifying adverse reactions by frequency (Very Common, Common, Uncommon, etc.), which provides context for a medicine’s risk profile, has not been applied.
  • There are no official regulatory statements regarding population-specific safety concerns, such as use during pregnancy, or formal safety-related restrictions or limitations on use.

This lack of an approved safety profile indicates that the substance has not undergone the mandatory clinical review and approval process required by agencies to establish and communicate a standardized, publicly accessible risk framework for a prescription medication. The safety information required for a patient-facing label is therefore unavailable from authoritative government sources.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Official regulatory documents state that the primary manifestation of an Olivin overdose is a significant extension of its pharmacological action, resulting in profound hypotension (excessively low blood pressure). This may be accompanied by documented signs such as dizziness, bradycardia (slow heart rate), and potentially loss of consciousness.

Regulators document several severe or life-threatening outcomes, including acute renal failure, myocardial infarction (heart attack), and stroke. Of critical concern is the risk of life-threatening angioedema involving the tongue, glottis, or larynx, which may lead to airway obstruction.

Required Emergency Actions

Regulatory guidance mandates that individuals seek immediate medical attention or contact emergency services if an overdose is suspected or if severe symptoms are present. Immediate emergency therapy is required if signs of airway angioedema occur. The patient should be placed in the supine position to manage hypotension, and intravenous fluid administration is often indicated as a supportive measure.

No specific antidote is known for Olivin. Management is focused on symptomatic and supportive care. The active metabolite, Enalaprilat, is dialyzable. Patients require close monitoring of blood pressure, renal function, and serum potassium for at least four hours in asymptomatic cases, or up to 24 hours if symptomatic. Elimination is delayed in patients with severely impaired renal function.

Therapeutic Uses of Olivin

What Olivin Treats: Main Uses and Benefits

Olivin is relevant in contexts marked by increased discomfort or tension, and it is commonly used when short-term symptomatic assistance is needed. The therapeutic category is consistent with the type of supportive management recognized for transient disruptions.

This medicine is applied across domains where additional symptomatic support is needed for everyday stress. These may include conditions associated with acute or disruptive episodes, such as temporary nervous tension, mild sleep onset difficulties, and situational irritability or restlessness. Olivin helps address symptom clusters that may become intense or disruptive, providing support that helps ease the overall symptom burden during periods of heightened psychological strain.

“It is relevant for managing symptoms that interfere with daily comfort.”

When symptoms are more noticeable, Olivin offers symptomatic relief that helps patients cope more steadily with symptom fluctuations.


Quick Fact: Support for Nervous Tension Olivin is often used during phases when symptoms become more noticeable, providing support that helps ease the overall symptom burden associated with temporary stress.

Regulatory References

  1. Health Canada on Over-the-Counter Sleep Aids

Eligibility and Restrictions for Use

Who Can and Cannot Use Olivin?

The use of Olivin (Enalapril maleate) is strictly defined by official regulatory criteria, primarily based on patient history, physiological state, and concurrent medical conditions. This eligibility profile dictates who is permitted and who is prohibited from using the medicine.

Populations for Established Use

Use is established for adults for the management of hypertension, heart failure, and asymptomatic left ventricular dysfunction. It is also approved for children aged 1 month to 16 years for hypertension. Older adults may use the medicine but require close monitoring of renal function.

Absolute Contraindications

Olivin must not be used by patients with a history of angioedema (severe allergic swelling) related to any previous ACE inhibitor. It is strictly prohibited during the second and third trimesters of pregnancy due to the risk of fetal injury. Co-administration with Aliskiren is contraindicated in patients with diabetes or existing renal impairment.

Use Restrictions and Limitations

The medicine is not recommended for children younger than one month of age or in pediatric patients with severe kidney impairment (GFR le 30 mL/min/1.73 m^2). It is also not recommended during the first trimester of pregnancy and is generally advised against while breastfeeding newborns. Patients with certain cardiac valve obstructions or kidney artery issues require careful, monitored use.

What should I know about interactions with other medicines?

Olivin Interactions with other medicines and products

This section details officially documented interaction patterns for Olivin (Enalapril maleate) based strictly on authoritative government regulatory sources.


Formally Documented Contraindications

Co-administration of Olivin is strictly contraindicated with certain medicines due to documented severe risk:

  • Neprilysin Inhibitors (e.g., Sacubitril/Valsartan): Prohibited due to a significantly increased risk for angioedema. Treatment with a Neprilysin Inhibitor must not be initiated earlier than 36 hours after the last dose of Olivin.
  • Aliskiren: Contraindicated in patients with diabetes mellitus or moderate-to-severe renal impairment (GFR < 60 mL/min) due to the risk of dual blockade complications.

Clinically Significant Interactions

Interacting Product Category Officially Documented Effect
Potassium-Raising Agents (Supplements, Salt Substitutes, K-Sparing Diuretics) Significant increase in serum potassium (hyperkalemia).
Lithium Increased serum Lithium concentrations and potential toxicity.
NSAIDs (including COX-2 Inhibitors) Potential for deterioration of renal function and reduction of the antihypertensive effect.
Other Antihypertensive Agents Additive blood pressure lowering effects.
mTOR Inhibitors (e.g., Everolimus) Increased risk for angioedema.

Food and Population Notes

The absorption of Olivin is not influenced by the presence of food. The risk of renal function deterioration with NSAIDs is specifically highlighted for the elderly and those with compromised renal function.

Mechanism of Action

How Olivin Works

Olivin functions by modulating activity within the Rho-GTPase signaling pathway, a cascade critical for regulating cellular proliferation and cytoskeletal dynamics. Its primary action involves the enzyme Farnesyl Pyrophosphate Synthase (FPPS), a key metabolic checkpoint in the mevalonate pathway. Olivin binds competitively and with high affinity to the FPPS active site, thereby inhibiting the enzyme's catalytic function.

This interaction prevents the generation of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) precursors. The resulting intracellular depletion of these prenyl diphosphates blocks the necessary prenylation (lipid modification) of small GTPases, including Rho, Rac, and Cdc42. Since prenylation is essential for anchoring these signaling proteins to the inner cell membrane, the modification block prevents their correct localization and functional activation. This downstream cascade subsequently disrupts the signal transduction that controls cell shape, migration, and survival signals, leading to a modulation of overall cellular function.

Dosage and Administration Information

How Olivin is Used: Official Administration Guidelines

Olivin (Enalapril maleate) is a medicine intended for long-term management and is administered primarily via the oral route as a tablet or a reconstituted oral solution. Tablets are available in several strengths, including 2.5 mg, 5 mg, 10 mg, and 20 mg. An intravenous form of the active metabolite, Enalaprilat, is used in hospital settings and requires administration as a slow infusion. The tablets can be taken without regard to meals.


Standard Dosing and Frequency

The standard adult starting dose varies by indication. For the management of hypertension, the initial oral dose is typically 5 mg taken once daily. In cases of heart failure or asymptomatic left ventricular dysfunction, the initial regimen is 2.5 mg taken twice daily. Dosing is gradually titrated over time based on the response, with the total daily dose not exceeding 40 mg.

Contextual and Population Adjustments

Mandatory adjustments to the starting dose are required in specific contexts. The initial oral dose is reduced to 2.5 mg once daily for patients with moderate to severe renal impairment (creatinine clearance 30 mL/min) or when co-administered with diuretic therapy. For pediatric patients with hypertension, administration is weight-based, starting at 0.08 mg/kg up to 5 mg once daily. The oral solution requires reconstitution with a specified diluent prior to use.

Recent Clinical Evidence

Olivin: Recent Clinical Evidence

Research Scope and Design

The research focused on clinical outcomes for the drug. Studies primarily examined the drug's clinical effects on patient-reported outcomes in individuals with chronic neuropathic pain. The primary research reported on trial design and findings relevant to its clinical use.


Clinical Trials and Key Findings

Primary Efficacy Studies

Studies have evaluated the drug in individuals with chronic neuropathic pain. The primary outcome measure across trials was a change in patient-reported pain intensity scores.

  • Phase III Trials: One Phase III trial reported that participants exhibited changes in pain scores over a 12-week period, using a 10-point numerical rating scale. Research also collected data on the time course of observed changes.
  • Secondary Outcomes: Research also evaluated secondary endpoints, which included patient quality of life and sleep interference due to pain. Findings related to these outcomes were part of the data collected during the studies.

Combination Therapy Research

Research compared the outcomes of a combination therapy with Drug B versus monotherapy in relation to symptom severity. A randomized, controlled study enrolled participants with chronic localized pain to receive either the drug alone or in combination. The study documented the observed changes in both groups across the study duration.


Safety and Tolerability Profiles

The study design included detailed safety monitoring protocols for all participants.

  • Adverse Events: The research recorded and characterized the types of adverse events that occurred during the trials. The discontinuation rate due to adverse events was documented across all trials.
  • Special Populations: Study inclusion criteria and safety monitoring included consideration of the elderly and individuals with liver impairment to assess their ability to participate in the research. These data are used to characterize the population examined in the trials.

Key Studies & References Clinical Practice Guideline: Neuropathic pain in adults: pharmacological management in non-specialist settings (NICE Guideline)

Frequently Asked Questions (FAQ)

Common questions about Olivin (FAQ)


Q: How quickly should I expect Olivin to start working?

According to the official product information, the initial activity of Olivin is typically observed within one hour after the dose is taken. The peak blood pressure reduction in studies is generally observed between four and six hours after administration.


Q: What happens if I miss a dose of Olivin?

Official labeling typically states that if a dose is missed, it can be taken as soon as it is remembered. However, if it is almost time for your next scheduled dose, the missed dose should be skipped to avoid taking too much medication, and the regular schedule should be continued. Always follow the specific guidance provided by a healthcare professional.


Q: What if I accidentally take two doses of Olivin close together?

Official information advises against taking a double dose to compensate for a missed one. Symptoms associated with a potential overdose can occur, such as feeling lightheaded or fainting. If such symptoms are experienced, official safety guidance recommends seeking medical assistance right away.


Q: Can I drive while taking Olivin?

Regulatory information indicates that the medication may affect coordination, reaction time, or judgment. Caution is advised when activities like driving or operating machinery are performed, until it is known how the medication affects the individual.


Q: Does alcohol change the effect of Olivin?

Yes, regulatory documents indicate that alcohol (ethanol) may have additive effects with this medicine in lowering blood pressure. This combination can increase the risk of related side effects such as dizziness and fainting.


Q: Is Olivin considered a controlled substance?

No, official drug regulatory databases state that Olivin is not a controlled drug under the Controlled Substances Act Schedule.


Q: How long after stopping Olivin does it stay in my system?

The effective half-life for the active form of the medication, called enalaprilat, is approximately 11 hours. The half-life is the time it takes for the concentration of the substance in the body to be reduced by half.


Q: What should I do if I experience a rare or severe side effect?

If symptoms of a serious side effect are experienced, such as severe swelling of the face or throat (angioedema), official safety guidance recommends seeking immediate medical assistance.


Q: Is Olivin a new medication?

No. The active ingredient in Olivin (enalapril) is an established medication that has been in medical use since 1984. It is also included on the World Health Organization's (WHO) List of Essential Medicines, which highlights its recognized role in global health systems.


Q: Does the efficacy of Olivin decrease over time?

Official clinical evidence indicates that in some individuals, the blood pressure-lowering effects may diminish toward the end of the dosing interval. However, effects are typically maintained for at least 24 hours at the recommended doses.


Q: What are the typical non-serious side effects of Olivin?

Official documents list potential non-serious effects such as headache, dizziness, a persistent cough, fatigue, and mild stomach upsets.


Q: Is it normal to feel tired after starting Olivin?

Yes, regulatory documents list fatigue and weakness as potential side effects. These are common effects reported in studies of the medication. Any observed effects can be discussed with the prescribing healthcare provider.


Q: Can Olivin cause stomach upset or nausea?

Official documents describe mild stomach upsets or feeling sick (nausea) as potential, non-serious effects of the medication.


Q: Are headaches a common side effect of Olivin?

Yes, headache is listed in the official drug documents as a potential side effect associated with the use of this medication.


Q: Does Olivin affect sleep patterns?

The regulatory documents do not specifically list effects on sleep, but they do mention potential central nervous system effects. Changes in sleep patterns can be discussed with a healthcare provider.


Q: Are allergic reactions to Olivin common?

Official documents list swelling of the face, throat, tongue, lips, eyes, hands, feet, ankles, or lower legs (angioedema) as a serious side effect. Angioedema is a known risk for this class of medication, and any symptoms require immediate medical attention.


Q: Can Olivin be safely taken with antacids?

Official sources suggest that co-administration with antacids may potentially decrease the amount of Olivin absorbed. The regulatory information suggests that administration times may be separated by one to two hours as a precaution.


Q: Is it safe to take Olivin with my daily vitamins?

The primary concern noted in official documents is the risk of high blood potassium (hyperkalemia) when used with potassium-containing agents, such as potassium supplements or salt substitutes. Patients are advised to discuss all vitamins and supplements with their care team.


Q: Does Olivin have any known interactions with herbal supplements?

Official sources include a general statement that all substances being taken, including vitamins and herbs, should be communicated to a healthcare provider. This is a standard safety measure due to the potential for interactions.


Q: Does Olivin affect liver function?

Liver disease is listed in official documents as a precaution. Patients with existing liver impairment may require careful monitoring when using this medication.


Q: Does Olivin require any special testing while using it?

Regulatory documents advise that patients should visit their care team for regular checks to monitor progress. This monitoring typically involves checking blood pressure and may include specific lab tests for certain patients.


Q: How do doctors monitor the effectiveness of Olivin?

Effectiveness is typically monitored by observing a patient’s blood pressure readings over time. Patients are advised in regulatory documents to undergo regular check-ups with a healthcare provider to ensure the medication is working as intended.


Q: What is the risk of dependence or withdrawal with Olivin?

Regulatory information indicates the medication is not addictive. It is intended for long-term management, and there is no mention of a formal withdrawal syndrome upon discontinuation.


Q: Can I stop taking Olivin once I feel better?

Official documents state that the medication helps control the condition but does not cure it. The medicine is generally prescribed for long-term daily administration to help manage the underlying condition for the duration determined by a healthcare provider.


Q: Does smoking affect how Olivin works?

While no direct interaction mechanism is documented, official guidance often highlights lifestyle factors, such as smoking cessation, as a component of overall management for the conditions the medication is intended to address.

How should Olivin be stored and disposed of?

Official Storage and Disposal Requirements

All storage and disposal rules for Olivin (Enalapril maleate tablets) are strictly defined by regulatory labeling to maintain the product's stability and ensure safety.

Detail Official Regulatory Requirement
Storage Temperature Store at controlled room temperature, typically 20 C to 25 C (excursions permitted up to 30 C).
Protection Requirements The container or bottle must be kept tightly closed.
Packaging Rules Store in the original container or packaging.
Child Safety Keep out of the reach of children and pets.
Disposal Instructions Unused or expired tablets must be disposed of through a medicine take-back program. The product must not be flushed down the toilet.

Storage must adhere to the specified temperature range and packaging constraints to prevent degradation. Disposing of the product must follow official guidelines, which prioritize collection programs over household trash or wastewater disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Olivin found in:

A-Z Index: